Sign In to View Organizational & Contract Pricing.
About This Item
Empirical Formula (Hill Notation):
C9H19ClN3O5P
CAS Number:
Molecular Weight:
315.69
UNSPSC Code:
12352200
PubChem Substance ID:
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Storage condition:
protect from light
Skip To
assay
≥98% (HPLC)
form
powder
storage condition
protect from light
color
light yellow
solubility
H2O: ≥1 mg/mL
originator
Servier
storage temp.
2-8°C
SMILES string
CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O
InChI
1S/C9H19ClN3O5P/c1-4-17-19(16,18-5-2)8(3)11-9(14)13(12-15)7-6-10/h8H,4-7H2,1-3H3,(H,11,14)
InChI key
YAKWPXVTIGTRJH-UHFFFAOYSA-N
Biochem/physiol Actions
Fotemustine is a third generation nitrosourea, chloroethylating agent used in the treatment of glioma and malignant melanoma.
Features and Benefits
This compound is a featured product for Apoptosis research. Click here to discover more featured Apoptosis products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Servier. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
A Silvani et al.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 32 Suppl 2, S255-S257 (2011-10-12)
Fotemustine (FTMS) is a third-generation nitrosourea, in preclinical studies, FTMS compared favorably with carmustine (BCNU) and lomustine (CCNU) against several human tumor cell lines. In conventional schedule, FTMS is administered at a dose of 100 mg/sqm/week for three consecutive weeks
Mario Balducci et al.
Neuro-oncology, 14(1), 79-86 (2011-10-14)
We explored the feasibility of concurrent palliative chemotherapy and low-dose fractionated radiotherapy (LD-FRT) in glioblastoma multiforme (GBM). Patients with recurrent/progressive GBM at least 3 months after the end of primary radiotherapy received 0.3 Gy twice daily with cisplatin and fotemustine
Aleksandra Ristić-Fira et al.
Radiation protection dosimetry, 143(2-4), 503-507 (2010-12-25)
Response of human HTB140 melanoma cells to proton irradiation in combination with fotemustine (FM) was investigated. Effects of these agents were analysed on cell proliferation and induction of apoptosis. Cells pretreated with 100- or 250-µM of FM were irradiated in
A Farolfi et al.
Journal of chemotherapy (Florence, Italy), 23(5), 300-305 (2011-10-19)
The liver is the primary site of metastases in most uveal melanoma patients. We retrospectively investigated intraarterial chemotherapy (IAC) as treatment for patients with hepatic melanoma metastases.Twenty-three patients (18 with uveal melanoma) received fotemustine (14 patients, 61.9%) or carboplatin (9
Complete response induced by fotemustine given as single agent in a patient with primary central nervous system non-Hodgkin aggressive lymphoma relapsed after high-dose chemotherapy and autologous stem cell support.
Elsa Pennese et al.
Leukemia & lymphoma, 52(11), 2188-2189 (2011-07-02)
Articles
Cell cycle phases (G1, S, G2, M) regulate cell growth, DNA replication, and division in proliferating cells.
Apoptosis regulation involves multiple pathways and molecules for cellular homeostasis.
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service